Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions

Invasive lobular carcinoma (ILC) accounts for up to 15% of all breast cancer (BC) cases and responds well to endocrine treatment when estrogen receptor α-positive (ER<sup>+</sup>) yet differs in many biological aspects from other ER<sup>+</sup> BC subtypes. Up to 30% of patie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	George Sflomos, Koen Schipper, Thijs Koorman, Amanda Fitzpatrick, Steffi Oesterreich, Adrian V. Lee, Jos Jonkers, Valerie G. Brunton, Matthias Christgen, Clare Isacke, Patrick W. B. Derksen, Cathrin Brisken
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	invasive lobular breast carcinoma experimental models metastasis PDX GEMM tumor organoids Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e9a688d788384c04ad1a7eade81bf161
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9a688d788384c04ad1a7eade81bf161
record_format	dspace
spelling	oai:doaj.org-article:e9a688d788384c04ad1a7eade81bf1612021-11-11T15:29:54ZAtlas of Lobular Breast Cancer Models: Challenges and Strategic Directions10.3390/cancers132153962072-6694https://doaj.org/article/e9a688d788384c04ad1a7eade81bf1612021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5396https://doaj.org/toc/2072-6694Invasive lobular carcinoma (ILC) accounts for up to 15% of all breast cancer (BC) cases and responds well to endocrine treatment when estrogen receptor α-positive (ER<sup>+</sup>) yet differs in many biological aspects from other ER<sup>+</sup> BC subtypes. Up to 30% of patients with ILC will develop late-onset metastatic disease up to ten years after initial tumor diagnosis and may experience failure of systemic therapy. Unfortunately, preclinical models to study ILC progression and predict the efficacy of novel therapeutics are scarce. Here, we review the current advances in ILC modeling, including cell lines and organotypic models, genetically engineered mouse models, and patient-derived xenografts. We also underscore four critical challenges that can be addressed using ILC models: drug resistance, lobular tumor microenvironment, tumor dormancy, and metastasis. Finally, we highlight the advantages of shared experimental ILC resources and provide essential considerations from the perspective of the European Lobular Breast Cancer Consortium (ELBCC), which is devoted to better understanding and translating the molecular cues that underpin ILC to clinical diagnosis and intervention. This review will guide investigators who are considering the implementation of ILC models in their research programs.George SflomosKoen SchipperThijs KoormanAmanda FitzpatrickSteffi OesterreichAdrian V. LeeJos JonkersValerie G. BruntonMatthias ChristgenClare IsackePatrick W. B. DerksenCathrin BriskenMDPI AGarticleinvasive lobular breast carcinomaexperimental modelsmetastasisPDXGEMMtumor organoidsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5396, p 5396 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	invasive lobular breast carcinoma experimental models metastasis PDX GEMM tumor organoids Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	invasive lobular breast carcinoma experimental models metastasis PDX GEMM tumor organoids Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 George Sflomos Koen Schipper Thijs Koorman Amanda Fitzpatrick Steffi Oesterreich Adrian V. Lee Jos Jonkers Valerie G. Brunton Matthias Christgen Clare Isacke Patrick W. B. Derksen Cathrin Brisken Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
description	Invasive lobular carcinoma (ILC) accounts for up to 15% of all breast cancer (BC) cases and responds well to endocrine treatment when estrogen receptor α-positive (ER<sup>+</sup>) yet differs in many biological aspects from other ER<sup>+</sup> BC subtypes. Up to 30% of patients with ILC will develop late-onset metastatic disease up to ten years after initial tumor diagnosis and may experience failure of systemic therapy. Unfortunately, preclinical models to study ILC progression and predict the efficacy of novel therapeutics are scarce. Here, we review the current advances in ILC modeling, including cell lines and organotypic models, genetically engineered mouse models, and patient-derived xenografts. We also underscore four critical challenges that can be addressed using ILC models: drug resistance, lobular tumor microenvironment, tumor dormancy, and metastasis. Finally, we highlight the advantages of shared experimental ILC resources and provide essential considerations from the perspective of the European Lobular Breast Cancer Consortium (ELBCC), which is devoted to better understanding and translating the molecular cues that underpin ILC to clinical diagnosis and intervention. This review will guide investigators who are considering the implementation of ILC models in their research programs.
format	article
author	George Sflomos Koen Schipper Thijs Koorman Amanda Fitzpatrick Steffi Oesterreich Adrian V. Lee Jos Jonkers Valerie G. Brunton Matthias Christgen Clare Isacke Patrick W. B. Derksen Cathrin Brisken
author_facet	George Sflomos Koen Schipper Thijs Koorman Amanda Fitzpatrick Steffi Oesterreich Adrian V. Lee Jos Jonkers Valerie G. Brunton Matthias Christgen Clare Isacke Patrick W. B. Derksen Cathrin Brisken
author_sort	George Sflomos
title	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
title_short	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
title_full	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
title_fullStr	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
title_full_unstemmed	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
title_sort	atlas of lobular breast cancer models: challenges and strategic directions
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e9a688d788384c04ad1a7eade81bf161
work_keys_str_mv	AT georgesflomos atlasoflobularbreastcancermodelschallengesandstrategicdirections AT koenschipper atlasoflobularbreastcancermodelschallengesandstrategicdirections AT thijskoorman atlasoflobularbreastcancermodelschallengesandstrategicdirections AT amandafitzpatrick atlasoflobularbreastcancermodelschallengesandstrategicdirections AT steffioesterreich atlasoflobularbreastcancermodelschallengesandstrategicdirections AT adrianvlee atlasoflobularbreastcancermodelschallengesandstrategicdirections AT josjonkers atlasoflobularbreastcancermodelschallengesandstrategicdirections AT valeriegbrunton atlasoflobularbreastcancermodelschallengesandstrategicdirections AT matthiaschristgen atlasoflobularbreastcancermodelschallengesandstrategicdirections AT clareisacke atlasoflobularbreastcancermodelschallengesandstrategicdirections AT patrickwbderksen atlasoflobularbreastcancermodelschallengesandstrategicdirections AT cathrinbrisken atlasoflobularbreastcancermodelschallengesandstrategicdirections
_version_	1718435278394228736

Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions

Ejemplares similares